Analyst Reco. BioAtla, Inc.

Equities

BCAB

US09077B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
1.495 ^USD	-1.64%		-5.97%	-39.23%

May. 23	BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting	CI
May. 15	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	Mar. 27	MT
HC Wainwright Lowers Price Target on BioAtla to $10 From $17, Maintains Buy Rating	Nov. 08	MT
JPMorgan Adjusts BioAtla Price Target to $14 From $17, Maintains Overweight Rating	23-09-25	MT
JPMorgan Adjusts Price Target on BioAtla to $19 From $23, Maintains Overweight Rating	23-04-03	MT
JPMorgan Adjusts BioAtla's Price Target to $19 From $23, Keeps Overweight Rating	23-04-03	MT
BTIG Adjusts Price Target on BioAtla to $13 From $68, Maintains Buy Rating	23-03-28	MT
JMP Securities Adjusts Price Target on BioAtla to $12 From $17, Keeps Outperform Rating	23-03-27	MT
HC Wainwright Adjusts Price Target on BioAtla to $17 From $20, Keeps Buy Rating	23-03-24	MT
EF Hutton Initiates BioAtla at Buy With $25 Price Target	23-01-05	MT
Credit Suisse Raises BioAtla's Price Target to $8 From $4, Keeps Neutral Rating	22-11-04	MT
JMP Securities Starts BioAtla at Market Outperform With $17 Price Target	22-09-15	MT
HC Wainwright Adjusts BioAtla's Price Target to $20 from $25, Keeps Buy Rating	22-08-10	MT
Credit Suisse Downgrades BioAtla to Neutral from Outperform, Says Outlook On Key Assets Uncertain After Disappointing BA3011 Update; Lowers Price Target to $5 from $35	22-05-05	MT
HC Wainwright Starts BioAtla at Buy With $25 Price Target	22-03-21	MT
Credit Suisse Trims BioAtla's Price Target to $35 from $68, Maintains Outperform Rating	22-02-14	MT
BIOATLA : JPMorgan Adjusts BioAtla's Price Target to $64 from $62, Keeps Overweight Rating	21-08-18	MT
BIOATLA : Roth Capital Starts BioAtla at Buy With $75 Price Target	21-06-28	MT
BIOATLA : BTIG Adjusts Price Target on BioAtla to $87 From $47, Maintains Buy Rating	21-03-26	MT
BIOATLA : Credit Suisse Starts BioAtla at Outperform With $49 Price Target	21-01-11	MT
BIOATLA : BTIG Starts BioAtla at Buy With $47 Price Target	21-01-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BioAtla, Inc.

Equities

BCAB

US09077B1044

Analyst Reco.

Filters